propranolol has been researched along with Sarcoma, Kaposi in 15 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Sarcoma, Kaposi: A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months." | 7.83 | Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol. ( Berti, E; Calvani, M; Defilippi, C; Della Bona, ML; Donzelli, G; Favre, C; Filippi, L; la Marca, G; Perrone, A; Tamburini, A, 2016) |
| "There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine." | 7.81 | Successful treatment of Kaposiform hemangioendothelioma with everolimus. ( Ito, S; Miyazaki, O; Mori, T; Nakazawa, A; Terashima, K; Uno, T, 2015) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 7.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 5.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| "Sirolimus is an effective therapy for children with kaposiform hemangioendothelioma with or without the Kasabach-Merritt phenomenon." | 3.88 | ( Dillingham, CS; Givner, LB; McLean, TW; Rinker, EK; Russell, TB, 2018) |
| "A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months." | 3.83 | Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol. ( Berti, E; Calvani, M; Defilippi, C; Della Bona, ML; Donzelli, G; Favre, C; Filippi, L; la Marca, G; Perrone, A; Tamburini, A, 2016) |
| "There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine." | 3.81 | Successful treatment of Kaposiform hemangioendothelioma with everolimus. ( Ito, S; Miyazaki, O; Mori, T; Nakazawa, A; Terashima, K; Uno, T, 2015) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 3.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 1.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Salido-Vallejo, R | 1 |
| González-Menchen, A | 1 |
| Alcántara-Reifs, C | 1 |
| España, A | 1 |
| Yu, L | 2 |
| Wei, L | 2 |
| Ma, L | 2 |
| Li, L | 2 |
| Navarro-Bielsa, A | 1 |
| Gil-Pallares, P | 1 |
| Diago-Irache, A | 1 |
| Martínez-Arnau, N | 1 |
| Gracia-Cazaña, T | 1 |
| Gilaberte, Y | 1 |
| Giorgio, CMR | 1 |
| Licata, G | 1 |
| Briatico, G | 1 |
| Babino, G | 1 |
| Fulgione, E | 1 |
| Gambardella, A | 1 |
| Alfano, R | 1 |
| Argenziano, G | 1 |
| Russell, TB | 1 |
| Rinker, EK | 1 |
| Dillingham, CS | 1 |
| Givner, LB | 1 |
| McLean, TW | 1 |
| Tlougan, BE | 1 |
| Lee, MT | 1 |
| Drolet, BA | 2 |
| Frieden, IJ | 1 |
| Adams, DM | 1 |
| Garzon, MC | 1 |
| Wang, Z | 1 |
| Li, K | 1 |
| Dong, K | 1 |
| Xiao, X | 1 |
| Zheng, S | 1 |
| Uno, T | 1 |
| Ito, S | 1 |
| Nakazawa, A | 1 |
| Miyazaki, O | 1 |
| Mori, T | 1 |
| Terashima, K | 1 |
| Korsaga-Somé, N | 1 |
| Maruani, A | 1 |
| Abdo, I | 1 |
| Favrais, G | 1 |
| Lorette, G | 1 |
| McAllister, SC | 1 |
| Hanson, RS | 1 |
| Manion, RD | 1 |
| Filippi, L | 1 |
| Tamburini, A | 1 |
| Berti, E | 1 |
| Perrone, A | 1 |
| Defilippi, C | 1 |
| Favre, C | 1 |
| Calvani, M | 1 |
| Della Bona, ML | 1 |
| la Marca, G | 1 |
| Donzelli, G | 1 |
| Hermans, DJ | 1 |
| van Beynum, IM | 1 |
| van der Vijver, RJ | 1 |
| Kool, LJ | 1 |
| de Blaauw, I | 1 |
| van der Vleuten, CJ | 1 |
| Chiu, YE | 1 |
| Blei, F | 2 |
| Carcao, M | 1 |
| Fangusaro, J | 1 |
| Kelly, ME | 1 |
| Krol, A | 1 |
| Lofgren, S | 1 |
| Mancini, AJ | 1 |
| Metry, DW | 1 |
| Recht, M | 1 |
| Silverman, RA | 1 |
| Tom, WL | 1 |
| Pope, E | 1 |
| Hochman, M | 1 |
2 reviews available for propranolol and Sarcoma, Kaposi
| Article | Year |
|---|---|
Medical management of vascular anomalies.
Topics: Adrenergic beta-Antagonists; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Syndrome; Pr | 2012 |
Management of vascular tumors.
Topics: Adrenergic beta-Antagonists; Child; Granuloma, Pyogenic; Hemangioendothelioma; Hemangioma; Humans; K | 2012 |
13 other studies available for propranolol and Sarcoma, Kaposi
| Article | Year |
|---|---|
Treatment With Oral Propranolol for Refractory Classic Cutaneous Kaposi Sarcoma.
Topics: Administration, Cutaneous; Humans; Propranolol; Sarcoma, Kaposi; Skin; Skin Neoplasms | 2022 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
Kaposi sarcoma of the penis successfully treated with oral propranolol.
Topics: Humans; Male; Penile Neoplasms; Penis; Propranolol; Sarcoma, Kaposi | 2023 |
Comparison between propranolol 2% cream versus timolol 0.5% gel for the treatment of Kaposi sarcoma.
Topics: Adrenergic beta-Antagonists; Humans; Propranolol; Sarcoma, Kaposi; Skin Neoplasms; Timolol | 2021 |
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Therapy, | 2018 |
Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Data Collection; Hemangioendothelioma; Hemangioma; H | 2013 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Synd | 2014 |
Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neoplasm; Everolimus; Hemang | 2015 |
[Kasabach-Merritt phenomenon (KMP) exacerbated by platelet transfusions].
Topics: Aspirin; Axilla; Combined Modality Therapy; Compression Bandages; Disease Progression; Disseminated | 2015 |
Propranolol Decreases Proliferation of Endothelial Cells Transformed by Kaposi's Sarcoma-Associated Herpesvirus and Induces Lytic Viral Gene Expression.
Topics: Adrenergic beta-Antagonists; CDC2 Protein Kinase; Cell Proliferation; Cyclin A2; Cyclin-Dependent Ki | 2015 |
Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol.
Topics: Drug Resistance, Neoplasm; Hemangioendothelioma; Humans; Infant, Newborn; Infant, Newborn, Diseases; | 2016 |
Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Disseminated Intravascular Coagulati | 2011 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioendothelioma; Hemangioma; Humans; Inf | 2012 |